Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
33643-46-8
Molecular formula
C13H16ClNO
Molecular weight
237.72 g/mol
Drug class
S-enantiomer of ketaminenon-selective, non-competitive NMDA receptor antagonist
Mechanism of action
Non-competitively antagonises NMDA glutamate receptors. Its antidepressant effects may involve downstream changes in synaptic plasticity and glutamatergic signalling; the precise mechanism underlying clinical response is not fully established.
Indications / reported uses
Treatment-resistant depression in adults, in conjunction with an oral antidepressant under the US product indication
Depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour, in conjunction with standard care; the label does not establish prevention of suicide or reduction of suicidal behaviour
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Esketamine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Esketamine Permitted Daily Exposure (PDE) report (the Esketamine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Esketamine Occupational Exposure Limit (OEL) report (the Esketamine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.